ARCHIVES

Biotheraputices To Reveal Plans for Expansion

This article is from The Cancer Letter archive.

Vol. 12 No. 32 | August 8, 1986

Download PDF Visit The Full Archive

Related Articles

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

June 29, 2012

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

June 24, 2011

Remaining DCT Recompetitions

November 7, 1980

Bast Named VP For Translational Research And Co-PI Of Core Grant At M. D. Anderson.

March 24, 2000

Institutinal Training Awards Hardest Hit As New Budget Cuts Will Slash Into Noncompeting Grants

March 13, 1981

NCI Adds $25 Million to R01, P01 Grant Pool In Fiscal 1990

February 23, 1990